Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: FCP
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: -

DekaLux-BioTech

+ Add to Watchlist

DKXBICF:LX

512.64 EUR 7.90 1.57%

As of 00:59:30 ET on 05/28/2015.

Snapshot for DekaLux-BioTech (DKXBICF)

Year To Date: +28.89% 3-Month: +8.05% 3-Year: +47.27% 52-Week Range: 272.42 - 525.58
1-Month: -1.48% 1-Year: +89.67% 5-Year: +35.79% Beta vs LUXXX: 0.72

Mutual Fund Chart for DKXBICF

No chart data available.
  • DKXBICF:LX 512.64
  • 1M
  • 1Y
Interactive DKXBICF Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for DKXBICF

DekaLux-BioTech is an open-end fund incorporated in Luxembourg. The objective is growth. The Fund invests in equity securities worldwide, that are issued by companies involved in the discovery, research, development, production, distribution, and marketing of biotechnological products for medical applications.

Inception Date: 06-02-2008 Telephone: 352-3409-39 Tel
Managers: ROGER VOGT
Web Site: -

Fundamentals for DKXBICF

NAV (on 2015-05-28) 512.64
Assets (M) (on 2015-05-28) 351.64
Fund Leveraged N
Minimum Investment -
Minimum Subsequent Investment -

Dividends for DKXBICF

Dividend Type Omitted
Dividend Frequency Annual
Last Dividend Net -
Dividend Yield (ttm) -

Fees & Expenses for DKXBICF

Front Load 3.75
Back Load -
Current Mgmt Fee 1.25
Redemption Fee -
12b1 Fee -
Expense Ratio 1.47

Top Fund Holdings for DKXBICF

Filing Date: 12/30/2014
Name Position Value % of Total
Celgene Corp 206,180 19,385,950 7.162%
Amgen Inc 140,559 18,801,621 6.946%
Regeneron Pharmaceuticals Inc 48,590 16,518,086 6.102%
Biogen Inc 57,110 16,110,138 5.952%
Gilead Sciences Inc 182,100 14,553,641 5.377%
Vertex Pharmaceuticals Inc 104,700 10,301,871 3.806%
Mylan NV 200,500 9,504,173 3.511%
Alexion Pharmaceuticals Inc 57,860 8,968,550 3.313%
Illumina Inc 54,610 8,501,567 3.141%
BioMarin Pharmaceutical Inc 78,850 5,972,121 2.206%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil